DoH Policies screened during the period: 1 October 2024 – 31 December 2024
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NI Firefighters’ Pension Schemes – The Firefighters’ Pension Schemes and Compensation Scheme (Amendment) (No. 2) Regulations (Northern Ireland) 2024 (PDF 308KB)
- Northern Ireland Rare Diseases Action Plan (PDF 319KB)
- Closure of Branch Surgery in Aghadowey (PDF 455KB)
- Three Year Health Service Plan (PDF 305KB)
- HSC Pension Scheme proposed amendments to scheme regulations - increase in member contributions to meet the required yield and miscellaneous amendment – The Health and Social Care Pension Scheme (Amendment) Regulations (Northern Ireland) 2025 (PDF 193KB
- Strategic Planning and Performance Group (SPPG) Procedure - Handback of General Medical Services (GMS) Contract (PDF 335KB)
- NICE Technology Appraisal TA1021 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (review of TA529) (PDF 279KB)
- NICE Public Health Guideline NG221 - Reducing sexually transmitted infections (PDF 191KB)
- NICE Clinical Guideline NG243 - Adrenal insufficiency: identification and management (PDF 200KB)
- NICE Technology Appraisal TA989 - Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (PDF 303KB)
- NICE Technology Appraisal TA1003 - Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (PDF 278KB)
- NICE Technology Appraisal TA1004 - Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (PDF 190KB)
- NICE Technology Appraisal TA1005 - Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (PDF 190KB)
- NICE Technology Appraisal TA1007 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (review of TA611) (PDF 190KB)
- NICE Technology Appraisal TA1008 - Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (PDF 192KB)
- NICE Technology Appraisal TA1009 - Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (PDF 192KB)
- NICE Technology Appraisal TA1010 - Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (PDF 191KB)
- NICE Technology Appraisal TA1011 - Belzutifan for treating tumours associated with von Hippel-Lindau disease (PDF 192KB)
- NICE Technology Appraisal TA1013 - Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (PDF 193KB)
- NICE Technology Appraisal TA1014 - Alectinib for adjuvant treatment of ALKpositive non-small-cell lung cancer (PDF 284KB)
- NICE Technology Appraisal TA1015 - Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (review of TA869) (PDF 285KB)
- NICE Technology Appraisal TA1016 - Elafibranor for previously treated primary biliary cholangitis (PDF 278KB)
- NICE Technology Appraisal TA1017 - Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (PDF 279KB)
- NICE Technology Appraisal TA1018 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (review of TA756) (PDF 277KB)
- NICE Technology Appraisal TA1019 - Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (PDF 277KB)
- NICE Technology Appraisal TA1022 - Bevacizumab gamma for treating wet age-related macular degeneration (PDF 278KB)
- NICE Technology Appraisal TA1012 - Avapritinib for treating advanced systemic mastocytosis (PDF 284KB)
- NICE Technology Appraisal TA1020 - Eplontersen for treating hereditary transthyretin-related amyloidosis (PDF 278KB)
- Valuing Medicines: A Strategy for the Sustainable Use of Medicines in Northern Ireland (PDF 394KB)
- NICE Clinical Guideline NG242 - Diabetic retinopathy: management and monitoring (PDF 197KB)
- Being Open Framework – Proposals for Consultation (PDF 326KB)
- HSC Pension Scheme proposed amendments to scheme regulations - increase in member contributions to meet the required yield and miscellaneous amendment – The Health and Social Care Pension Scheme (Amendment) Regulations (Northern Ireland) 2025 (PDF 232KB